|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] The Sector At A Glance Key Insights On The Pharmaceutical Sector Of Belgium Belgium’s pharmaceuticals market is characterised by high per-capita spend, low generic penetration and widespread cost-cutting measures. Due to its mature status, as well as small population, growth opportunities are limited, although informed patients are driving the uptake of the latest technologies and medications. The value of the pharmaceutical market is currently US$4.7bn, and 5-6% year-on-year (y-oy) growth is forecast through to 2010, when the market is predicted to reach US$5.9bn in value. A reference pricing system was introduced in 2001 to encourage the wider dispensing of generic drugs. Under the scheme, pharmaceuticals are reimbursed on the basis of the price of the generic drug, which was initially set at 16% less than that of the equivalent branded product. Over time, the Belgian government has progressively reduced the reference price from 84% (until July 2002), 80% (until January 2003) to 74% of the price of the originator medicine (at July 2005). The rate now stands at 30% below that of the equivalent branded product, although the penetration of generic medicine still remains well below that in Germany and the UK. BMI’s adjusted Business Environment Rankings for Western Europe reveal that Belgium places six, just ahead of Spain and the Netherlands. The country scores highly for political and economic risk and also for market growth potential, but is disadvantaged by its small market size, low prices and limited potential for growth, especially in the face of the need to contain healthcare costs. Domestic industry is relatively limited in reach, with the exception of Solvay and UCB Pharma. Many multinationals use Belgium as an international distribution centre, meaning that import/export trade in pharmaceutical products far exceeds the value of the domestic market. In addition, the country is a major manufacturing hub, particularly for biopharmaceuticals. Both GlaxoSmithKline Biologicals and Solvay have vaccine production capabilities in Belgium, with the country representing one of the main global centres of vaccine manufacture. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummaryBelgium Pharmaceuticals & Healthcare Industry SWOT Belgium Political SWOT Belgium Economic SWOT Chapter 2 - Belgium: Business Environment RankingWestern Europe Table: Western Europe Business Environment Rankings Business Environment Ranking Economics – Long-Term Risk Politics – Long-Term Risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Belgium: Market SummaryRegulatory Regime Intellectual Property Developments Pricing And Reimbursement Regime Pricing And Reimbursement Developments Chapter 4 - Industry DevelopmentsHealthcare Sector Table: Healthcare Budget In Belgium (US$bn) Health Profile Table: Main Causes of Death Recent Healthcare Sector Developments Pharmaceuticals Sector Recent Company Developments Generics Sector R&D Sector Healthcare Information Technology (IT) Developments Chapter 5 - Industry Forecast ScenarioOverall Market Forecast Table: Belgium Drug Market Forecast Indicators Key Growth Factors – Industry Table: Belgium Health Expenditure Indicators Key Growth Factors – Macroeconomic Table: Belgium – Macroeconomic Forecasts Prescription Market Forecast Table: Belgium Prescription Drugs Market Forecast Indicators OTC Market Forecast Table: Belgium OTC Drugs Market Forecast Indicators Generics And Branded Market Forecast Table: Belgium Generics And Branded Drug Market Forecast Indicators Export/Import Forecasts Table: Belgium Pharmaceuticals Exports And Imports Forecasts Other Healthcare Data Forecasts Table: Belgium Healthcare Data Forecast Indicators Key Risks To CHAPTER - BMI Forecasts Chapter 6 - Competitive LandscapeTable: Leading Pharmaceutical Company Sales In Belgium, 2004-2005 Chapter 7 - Company MonitorLeading Multinational Manufacturers GlaxoSmithKline (GSK) Pfizer Novartis Sanofi-Aventis Merck & Co Janssen Pharmaceutica Leading Indigenous Manufacturers UCB Pharma Solvay Omega Pharma Chapter 8 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Technical Process Pharmaceutical Industry Sources Chapter 9 - Appendix: Demographic DataCountry Snapshot: Belgium Demographic Data Section 1: Population: Table: Demographic Indicators (2005) Table: Rural/Urban Breakdown Section 2: Education & Healthcare Table: Education Table: Healthcare: Vital Statistics Table: Healthcare: Expenditure Section 3: Labour Market And Spending Power Table: Employment Indicators Table: Consumption And Stratification
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of European Pharmaceutical & Healthcare Sources[TOP] BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||